药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
GS-5745
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with GS-5745.
Mecasermin
Luspatercept
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Luspatercept.
Mecasermin
Aducanumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Aducanumab.
Mecasermin
Ascrinvacumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ascrinvacumab.
Mecasermin
Cixutumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cixutumumab.
Mecasermin
Inclacumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Inclacumab.
Mecasermin
Etaracizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Etaracizumab.
Mecasermin
Ganitumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ganitumab.
Mecasermin
Zalutumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Zalutumumab.
Mecasermin
Etrolizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Etrolizumab.
Mecasermin
Tralokinumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tralokinumab.
Mecasermin
Dupilumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dupilumab.
Mecasermin
Fasinumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fasinumab.
Mecasermin
Simtuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Simtuzumab.
Mecasermin
Duligotuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Duligotuzumab.
Mecasermin
Gevokizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Gevokizumab.
Mecasermin
Sotatercept
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sotatercept.
Mecasermin
Tarextumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tarextumab.
Mecasermin
Fulranumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fulranumab.
Mecasermin
Patritumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Patritumab.